Durvalumab with paclitaxel/carboplatin + bevacizumab then maintenance durvalumab, bevacizumab + olaparib in patients with newly diagnosed advanced ovarian cancer without a tumour brca1/2 mutation: Results from the DUO-O/ENGOT-OV46/AGO-OVAR 23/GOG-3025 trial Meeting Abstract
| Authors: | Marth, C.; Park-Simon, T. W.; Aghajanian, C.; Reuss, A.; Nishio, S.; Lim, M. C.; Rubio-PeĢrez, M. J.; Vardar, M. A.; Scambia, G.; Sabatier, R.; Haslund, C.; Colombo, N.; Chudecka-Glaz, A.; Lheureux, S.; Huygh, G.; Schochter, F.; Wenham, R. M.; Okamoto, A.; Day, E.; Harter, P. |
| Abstract Title: | Durvalumab with paclitaxel/carboplatin + bevacizumab then maintenance durvalumab, bevacizumab + olaparib in patients with newly diagnosed advanced ovarian cancer without a tumour brca1/2 mutation: Results from the DUO-O/ENGOT-OV46/AGO-OVAR 23/GOG-3025 trial |
| Meeting Title: | 2023 International Meeting of the European Society of Gynaecological Oncology (ESGO) |
| Journal Title: | International Journal of Gynecological Cancer |
| Volume: | 33 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2023 Sep 28-Oct 1 |
| Meeting Location: | Istanbul, Turkey |
| ISSN: | 1048-891X |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2023-09-01 |
| Start Page: | A428 |
| End Page: | A429 |
| Language: | English |
| ACCESSION: | WOS:001264297900900 |
| DOI: | 10.1136/ijgc-2023-ESGO.899 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1120 -- Source: Wos |
